Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy

Iris Noyman, Dana Ekstein, Firas Fahoum, Moshe Herskovitz, Ilan Linder, Bruria Ben Zeev, Sara Eyal

Research output: Contribution to journalComment/debate

Abstract

Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate-to-strong enzyme-inducing antiseizure medications (ASMs) and everolimus should not be treated with nirmatrelvir/ritonavir; rectal diazepam may be used as an alternative to buccal midazolam; doses of ASMs that are cytochrome P450 (CYP3A4) substrates might be adjusted; and patients treated with combinations of nirmatrelvir/ritonavir and ASMs that are CYP3A4 substrates or lamotrigine should be monitored for drug efficacy and adverse drug reactions.

Original languageEnglish
Pages (from-to)1276-1278
Number of pages3
JournalEpilepsia
Volume63
Issue number5
DOIs
StatePublished - May 2022

Keywords

  • COVID-19
  • CYP3A4
  • antiepileptic drugs
  • antiseizure medications
  • drug–drug interactions

Fingerprint

Dive into the research topics of 'Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy'. Together they form a unique fingerprint.

Cite this